Clinical

The company is conducting a Phase 1a open-label, non-randomized, multi-center clinical trial of intratumoral IVX037 in people with micro satellite-stable (MSS) colorectal or gastroesophageal cancer metastatic to liver, or advanced ovarian cancer. As of October 2023 Cohorts 1 and 2 are fully recruited and Cohort 3 is open. A Phase 1b study using IVX37 in combination with a checkpoint inhibitor is planned to commence in early 2024.

Details of the study can be found at clinicialtrials.gov as well as on the company’s investor deck available here.